Earlybird Venture Capital’s Health portfolio Swiss biopharma company Oculis focused on developing transformative ophthalmic treatments, announced that it has closed an oversubscribed US$57 million Series C financing. The round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur, Earlybird, Funds managed by Tekla Capital Management, Pivotal
READ MORE
